Jump to navigation
One-third of the sample who regularly used ecstasy had tested their illicit drugs in the last year.
The aim of this study was to assess industry strategic approaches as communicated in articles published in a leading Australian alcohol trade magazine to provide insights for policy makers and advocacy groups.
This review examines evidence for the effectiveness of cannabinoids in chronic noncancer pain (CNCP) and addresses gaps in the literature.
There is a need to better understand risk for adverse outcomes during and after OAT, and for innovative approaches to identifying people at greatest risk of adverse outcomes.
Prescribers in Australia are likely to see increasing numbers of patients experiencing difficulties with pharmaceutical opioid use.
This paper looks at the practice of 'double dropping’ - consuming two drugs simultaneously, typically two ecstasy pills - by Australian festival-goers.
This paper looks at the prevalence, risk factors, and clinical and cognitive features of methamphetamine-associated psychosis.
Opioid use disorder (OUD) is associated with a high risk of premature death. Medication-assisted treatment (MAT) is the primary treatment for opioid dependence.
Whole‐of‐community interventions aim to reduce alcohol and other drug (AOD) use and harms by mobilizing community leaders, organizations and policy‐makers to respond effectively to AOD use.
The study estimated the prevalence and frequency of amphetamine use in a cohort of Australians aged in their mid‐30s and compared this with National Drug Strategy Household survey (NDSHS) estimates
The high prevalence of post-traumatic stress disorder (PTSD) among people with heroin dependence and its impact on short term outcomes has been well established.
The national centres are supported by funding from the Australian Government under the Drug and Alcohol Program
Page last updated: Thursday 6 August 2020